Susquehanna International Group, LLP Beyond Spring Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	SELL	$0.85 - $3.63 $99,620 - $425,436	-117,200 Reduced 86.88%	17,700 $63,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.12 $3,685 - $6,160	5,500 Added 4.25%	134,900 $121,000
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.16 $13,500 - $20,880	-18,000 Reduced 12.21%	129,400 $103,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.39 $9,434 - $14,733	-10,600 Reduced 6.71%	147,400 $173,000
Q1 2023 May 16, 2023	BUY	$1.06 - $3.05 $42,824 - $123,220	40,400 Added 34.35%	158,000 $176,000

Q4 2022 Feb 14, 2023	BUY	$0.56 - $2.61 $12,432 - $57,942	22,200 Added 23.27%	117,600 $221,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $1.81 $15,794 - $26,969	14,900 Added 18.51%	95,400 $94,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $62,601 - $147,364	-55,400 Reduced 40.77%	80,500 $116,000
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $278,208 - $829,656	-165,600 Reduced 54.93%	135,900 $299,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $496,871 - $2.08 Million	123,600 Added 69.48%	301,500 $1.37 Million
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $1.65 Million - $5.57 Million	177,900 New	177,900 $2.8 Million

5.44M

30.3K

1.8K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $95.4M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.